Lifevantage Q3 2024 Adj EPS $0.21 Beats $0.16 Estimate, Sales $48.245M Miss $52.182M Estimate

5/2/24 5:04:01 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LFVN alert in real time by email

Lifevantage (NASDAQ:LFVN) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.16 by 31.25 percent. This is a 162.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $48.245 million which missed the analyst consensus estimate of $52.182 million by 7.54 percent. This is a 10.23 percent decrease over sales of $53.741 million the same period last year.

Get the next $LFVN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LFVN

Date	Price Target	Rating	Analyst

More analyst ratings

$LFVN
Leadership Updates

Live Leadership Updates

LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service
SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever
8/26/24 4:05:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care
LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24
SALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVantage, its activating products, and the Company's industry-leading compensation plan designed to meet modern sharers by supporting both product sellers and team builders. The Open House call on the 23rd will feature a Q&A with LifeVantage President and CEO, Steve Fife, Chief Sales Officer, Kristen Cunningham, and Regional Vice President of Sales, Jake Hines. The discussion will include the e
7/22/24 6:27:51 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care
LifeVantage Appoints Dayton Judd to the Board of Directors
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company's Board of Directors (the "Board"), effective immediately, in an expansion of the Board. The Company has had discussions with Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with certain of their affiliates, the "Radoff-Sudbury Group"), which owns approximately 12.6% of the Company's outstanding stock, since the Company's fiscal year 2024 annual meeting of shareholders held on November 6, 2023. During these dis
2/15/24 4:05:00 PM ET
$FTLF
$LFVN
$OPXS
Medicinal Chemicals and Botanical Products
Health Care
Biotechnology: Pharmaceutical Preparations
Electronic Components

$LFVN
Financials

Live finance-specific insights

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024. First Quarter Fiscal 2025 Summary*: Revenue of $47.2 million, a decrease of 8.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was down approximately 7.7%;Revenue in the Americas decreased 4.2%, and revenue in Asia/Pacific & Europe decreased 19.7%. Excluding the negative impact of foreign currency fluctuations, first quarter rev
10/29/24 4:07:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care
LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock, which will be paid December 16, 2024 to all stockholders of record at the close of business on December 2, 2024. About LifeVantage Corporation LifeVantage Corporation® (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod
10/29/24 4:06:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care
LifeVantage to Announce First Quarter Fiscal Year 2025 Results on October 29, 2024
SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2024, after the stock market closes on Tuesday, October 29, 2024. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours
10/15/24 4:05:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care

LifeVantage to Participate at the Sidoti Micro Cap Conference
SALT LAKE CITY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the Sidoti Micro Cap Conference, to be held November 13-14, 2024. Mr. Fife and Mr. Aure will meet virtually with investors and present at approximately 1:00 p.m. Eastern Time on Wednesday, November 13, 2024. A live webcast of their presentation will be accessible on the News & Events section of the Company's Investor Relations website at https://lifevanta
11/7/24 4:05:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care
LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024. First Quarter Fiscal 2025 Summary*: Revenue of $47.2 million, a decrease of 8.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was down approximately 7.7%;Revenue in the Americas decreased 4.2%, and revenue in Asia/Pacific & Europe decreased 19.7%. Excluding the negative impact of foreign currency fluctuations, first quarter rev
10/29/24 4:07:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care
LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock, which will be paid December 16, 2024 to all stockholders of record at the close of business on December 2, 2024. About LifeVantage Corporation LifeVantage Corporation® (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod
10/29/24 4:06:00 PM ET
$LFVN
Biotechnology: Pharmaceutical Preparations
Health Care

Lifevantage Q3 2024 Adj EPS $0.21 Beats $0.16 Estimate, Sales $48.245M Miss $52.182M Estimate

Chat with this insight

Recent Analyst Ratings for $LFVN

$LFVN Market Insights

Live Market Insights

Lifevantage Sees FY24 Revenue $202M-$205M